Liraglutide vs Semaglutide
| Attribute | Liraglutide Saxenda, Victoza | Semaglutide GLP-1 receptor agonist |
|---|---|---|
| Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
| Best known for | First-generation daily GLP-1 agonist research | Weight loss and blood sugar research |
| In plain English | The original once-daily GLP-1; semaglutide is the once-weekly evolution. | Semaglutide mimics the hormone your gut releases when you eat. The brain reads it as 'we're full,' appetite drops, and stomach emptying slows down. |
| How it works | Activates GLP-1 receptors to enhance glucose-dependent insulin release, suppress glucagon, and slow gastric emptying. | Activates the GLP-1 receptor in the pancreas, brain, and gut — increasing insulin secretion, slowing gastric emptying, and reducing appetite through hypothalamic signaling. |
| Researchers study | Type 2 diabetes, obesity, and cardiovascular outcomes. | Glycemic control, weight reduction, cardiovascular outcomes, and emerging research in addiction and neuroinflammation. |
| Internet discussion | Discussed as 'first-gen Ozempic' on GLP-1 forums. | The internet talks about semaglutide constantly — 'Ozempic face,' food noise reduction, alcohol cravings dropping, and dose-titration questions. |
Liraglutide
First-generation daily GLP-1 agonist research
The original once-daily GLP-1; semaglutide is the once-weekly evolution.
Activates GLP-1 receptors to enhance glucose-dependent insulin release, suppress glucagon, and slow gastric emptying.
Type 2 diabetes, obesity, and cardiovascular outcomes.
Discussed as 'first-gen Ozempic' on GLP-1 forums.
Liraglutide is a daily GLP-1 receptor agonist researched for glucose control and weight loss.
Semaglutide
Weight loss and blood sugar research
Semaglutide mimics the hormone your gut releases when you eat. The brain reads it as 'we're full,' appetite drops, and stomach emptying slows down.
Activates the GLP-1 receptor in the pancreas, brain, and gut — increasing insulin secretion, slowing gastric emptying, and reducing appetite through hypothalamic signaling.
Glycemic control, weight reduction, cardiovascular outcomes, and emerging research in addiction and neuroinflammation.
The internet talks about semaglutide constantly — 'Ozempic face,' food noise reduction, alcohol cravings dropping, and dose-titration questions.
Semaglutide is the reference GLP-1 agonist — well-studied for blood sugar control and significant weight reduction.